Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nutex Health Inc. (NUTX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nutex Health is a Houston-based, physician-led healthcare management and operations company with a Hospital Division and a Population Health Management Division, and its filings explain how these segments are reflected in its financial statements and risk disclosures.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Nutex Health presents consolidated financial statements, segment revenue for its hospital and population health management divisions, details on operating costs, noncontrolling interests and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Recent filings also describe restatements of prior financial statements, including reclassification of non-cash stock-based compensation obligations related to under-construction and ramping hospitals, and explain that these adjustments were non-cash and did not materially affect key metrics such as revenue, liquidity, operating cash flow, Adjusted EBITDA or patient visits for the periods presented.
Current reports on Form 8-K document material events such as the release of quarterly and annual earnings, notices from Nasdaq regarding timely filing requirements and subsequent confirmation of regained compliance, appointment of senior executives, authorization of stock repurchase programs and disclosure of litigation, including a derivative action filed in federal court. These 8-K filings help investors understand significant developments between periodic reports.
On Stock Titan, Nutex Health filings are updated in near real time from EDGAR and are accompanied by AI-powered summaries that highlight key points from lengthy documents. Users can quickly see where Nutex Health discusses topics such as arbitration-related revenue through the Independent Dispute Resolution (IDR) process, capital structure, stock-based compensation, and legal or regulatory matters. The filings page also surfaces ownership and transaction data from forms such as Form 4, enabling readers to review insider transactions alongside the company’s broader financial and operational disclosures.
Nutex Health (NUTX)Wesley Shane Bamburg. The filing states that no securities are beneficially owned by the reporting person as of the event date.
The event date is 10/15/2025, and the form was filed by one reporting person. This is a routine Section 16 initial ownership report confirming no current holdings.
Nutex Health Inc. filed an 8‑K announcing it issued a press release with anticipated preliminary financial metrics for the period ended September 30, 2025, furnished as Exhibit 99.1.
The company also updated its Nasdaq listing status. Nutex is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to not timely filing its Quarterly Report on Form 10‑Q for the period ended June 30, 2025. The company submitted a compliance plan on October 15, 2025, and Nasdaq granted an extension on October 16, 2025 to file the June 30, 2025 Form 10‑Q by December 12, 2025. If Nutex does not file by December 12, 2025, Nasdaq staff will issue a delisting notice, which the company may appeal to a Nasdaq Hearings Panel.
Nutex Health, Inc. appointed Michael Bamburg as Chief Operating Officer and disclosed the principal terms of his employment agreement dated September 16, 2025. Bamburg, age 43, joins from HCA Houston Healthcare with a background in payor contracting and provider operations and holds a B.S. in Healthcare Administration and an MBA. The two-year agreement provides a base salary of $415,000 with automatic two-year extensions unless timely notice is given, eligibility for an annual cash bonus up to 60% of base salary, participation in long-term incentive awards valued up to 60% of base salary if granted, and a $100,000 signing bonus payable over four quarters if he remains employed at least 12 months. The agreement includes twelve months' severance and health subsidy if terminated without cause or for good reason, and standard accrual and reimbursement provisions. The filing incorporates the full agreement as Exhibit 10.1.
Nutex Health, Inc. appointed Michael L. Reed as Lead Independent Director effective
FAQ
What is the current stock price of Nutex Health (NUTX)?
What is the market cap of Nutex Health (NUTX)?
